Last reviewed · How we verify
Live attenuated Japanese encephalitis virus — Competitive Intelligence Brief
phase 2
Biologic
Live · refreshed every 30 min
Target snapshot
Live attenuated Japanese encephalitis virus (Live attenuated Japanese encephalitis virus) — Sanofi.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Live attenuated Japanese encephalitis virus TARGET | Live attenuated Japanese encephalitis virus | Sanofi | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Live attenuated Japanese encephalitis virus CI watch — RSS
- Live attenuated Japanese encephalitis virus CI watch — Atom
- Live attenuated Japanese encephalitis virus CI watch — JSON
- Live attenuated Japanese encephalitis virus alone — RSS
Cite this brief
Drug Landscape (2026). Live attenuated Japanese encephalitis virus — Competitive Intelligence Brief. https://druglandscape.com/ci/live-attenuated-japanese-encephalitis-virus. Accessed 2026-05-18.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab